The Kennedy Trust

The Kennedy Trust

The Kennedy Trust was established in 1965 by Mathilda Kennedy and her husband, Terence Kennedy. Mathilda was the daughter of Michael Marks, the co-founder of the British retail giant Marks & Spencer, and the trust's endowment originates from that family fortune. Rather than operating as a conventional single-family office, the entity is structured as a charitable trust that functions as a long-term asset manager, directing its investment returns entirely toward medical research. Its founding grant established the Kennedy Institute of Rheumatology at the University of Oxford, which remains the trust's primary scientific partner. The trust allocates across a multi-asset portfolio designed to fund its grant-making in perpetuity. Its investment strategy spans direct holdings in UK commercial real estate, including positions in the Savills Charity Property Fund, Mayfair PITCH, and the CCLA COIF Charities Property Fund. On the liquid side, the trust deploys capital across growth equities and other managed strategies, though specific public-equity positions are not publicly itemized. The geographic focus is concentrated in the United Kingdom, with its real assets held in London commercial properties and its research funding directed to UK-based institutions, primarily the University of Oxford. The trust's internal team remains deliberately lean, with a board of trustees that includes private equity specialist Joe Cronly, who brings direct investment expertise to the endowment's oversight. The Kennedy Network, a professional community of over 100 scientists and fellows funded by the trust, serves as an unusual sourcing and diligence channel for evaluating the translational impact of its research grants. The trust is also a member of the Association of Medical Research Charities, aligning it with the governance standards of the UK's major health-research funders. The Kennedy Trust occupies a distinct structural space — neither a traditional family office managing multi-generational wealth for living heirs, nor a pure grant-making foundation with outsourced investment management. It runs its endowment internally with a trustee-led investment committee, directly owning real estate and directing a portfolio whose sole beneficiary is a single disease-research mandate. That operational concentration on rheumatology, sustained for nearly six decades, distinguishes it from broader charitable allocators like the Wellcome Trust.